Novo Nordisk (NVO) and Eli Lilly & Co. (NYSE:LLY), the global leaders in obesity medications, are now facing their first ...

By Siddhi Mahatole and Puyaan Singh (Reuters) -INmune Bio said on Monday its experimental Alzheimer's drug failed to improve ...

Big Pharmas like Eli Lilly, Sanofi and Novartis headed back to the dealmakers table multiple times, with 32 total deals ...

Options traders leaned bearish on LLY stock, but market demand data reveals conditional odds that may support near-term ...

These popular medications are now at the center of a major weight loss drug lawsuit. Find out which drugs and involved and ...

Total adverse events of heart failure or all-cause mortality were reduced with empagliflozin, regardless of kidney function.

China NMPA approves Innovent’s mazdutide, first dual GCG/GLP-1 receptor agonist for chronic weight management: San Francisco, US Monday, June 30, 2025, 12:00 Hrs [IST] Innovent ...

A federal judge has rejected Johnson & Johnson’s challenge to block its proposed rebate model under the 340B Drug Pricing Program, Bloomberg Law reported June 27. Judge Rudolph Contreras of the U.S.

China has approved a new weight-loss drug that is poised to rival Novo Nordisk and Eli Lilly's popular GLP-1 treatments, ...

In a European study, higher consumption of fruits, vegetables, legumes, and potatoes was associated with a reduced risk of ...

Lifestyle therapy may not be enough to improve outcomes for patients with HF and obesity, but careful risk evaluation and ...

The post Big, Beautiful Bill Finds Its Opponents appeared first on Reason.com.